🇺🇸 FDA
Pipeline program

00 mg/mL Concentrate for solution for infusion, VHB937

CVHB937A12201

Phase 2 small_molecule active

Quick answer

00 mg/mL Concentrate for solution for infusion, VHB937 for Alzheimer’s disease is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Alzheimer’s disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials